No no no. kad, Prana calls itself a neurodegenerative drug developer right now although they have done nothing except talk about developing something. Becoming a "neurodegeneration(sic) drug developer with a wide platform of drugs to follow" (LOL) doesn't mean that they will be licensed to sell anything. That will come only after the end of HD Phase III with a large number of appropriate patients who demonstrate safety and replicable efficacy.
The data from Reach2HD Phase II is nothing to celebrate now before even starting their very first late-stage studies. It is fool-hardy to do so, as many experienced biotechs have found.
LLY change at the top., page-31
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $111.6K | 38.04M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1328757 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 141111606 | 51 |
View Market Depth
| Last trade - 16.10pm 17/10/2024 (20 minute delay) ? |
| ATH (ASX) Chart |